
Key Points
- 01FDA sets April 22, 2027 target action date for two IDVYNSO filings
- 02Merck to show Phase 3 data on once‑weekly ISL/LEN at HIV Glasgow 2026
- 03Adult enrollment completed in two Phase 3 alimatravir PrEP trials
- 04Glasgow presentations span daily, weekly and monthly oral HIV regimens
Merck details oral HIV plans ahead of 2027 FDA decision
Merck has outlined progress across its oral HIV treatment and prevention portfolio, highlighting an upcoming U.S. Food and Drug Administration decision on IDVYNSO and new late‑stage trial data to be shown at HIV Drug Therapy Glasgow 2026. The FDA has accepted two supplemental New Drug Applications for IDVYNSO, a once‑daily, two‑drug single‑tablet regimen that combines 100 mg doravirine and 0.25 mg islatravir, and has set April 22, 2027, as the Prescription Drug User Fee Act target action date for both filings. One application is based on Phase 3 Trial 053 in adults who had not previously received antiretroviral treatment, while the other is based on Phase 3 Trials 051 and 052 to include 96‑week data in virologically suppressed adults. IDVYNSO is approved in the United States and Japan for adults with virologically suppressed HIV‑1 infection to replace a current antiretroviral regimen in patients with HIV‑1 RNA below 50 copies per mL on a stable regimen.
As part of existing safety information, Merck has reported a single case of severe immune thrombocytopenia in a participant 32 days after initiating IDVYNSO, which resolved after discontinuation of the regimen alongside treatments including corticosteroids and intravenous immunoglobulin. Guidance for use of IDVYNSO includes cautions on drug interactions with strong cytochrome P450 3A inducers and with agents affecting deoxycytidine kinase and adenosine deaminase pathways, and it does not recommend use in patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m² or in those on dialysis. IDVYNSO is described as a complete regimen, meaning co‑administration with other antiretroviral medications for HIV‑1 treatment is not recommended.
Phase 3 data to anchor HIV Glasgow 2026 program
At HIV Drug Therapy Glasgow 2026, scheduled for November 8–11 in Glasgow, Scotland, Merck plans to present new data across its HIV pipeline and portfolio. The conference agenda includes Phase 3 subgroup analyses and patient‑reported outcomes for an investigational once‑weekly oral combination of islatravir and lenacapavir, referred to as ISL/LEN. These Phase 3 ISLEND‑1 and ISLEND‑2 data will feature week 48 safety and efficacy subgroup analyses; previously presented Phase 3 findings showed maintained viral suppression with the once‑weekly regimen.
Presentations will also cover once‑daily IDVYNSO, with a focus on resistance, weight and patient‑reported outcomes in adults living with HIV‑1. Additional material will address an investigational once‑weekly oral regimen of islatravir and ulonivirine, including a Phase 1 study of ulonivirine’s absorption, metabolism and excretion in adults without HIV, and an analysis indicating once‑weekly dosing provides a week of forgiveness after a missed dose. Merck says the data will add detail on the performance and tolerability of emerging oral regimens across different dosing schedules.
Alimatravir monthly PrEP program reaches enrollment milestone
Merck is also advancing alimatravir, an investigational once‑monthly oral option for HIV‑1 pre‑exposure prophylaxis. Alimatravir, also known as AMI or MK‑8527, is being evaluated in two ongoing Phase 3 trials as a potential once‑monthly prevention regimen. Adult enrollment in both Phase 3 trials has now been completed, marking a key step in the development program.
At HIV Glasgow 2026, Merck will present participant demographics from the adult cohorts of the EXPrESSIVE‑10 and EXPrESSIVE‑11 trials, which are assessing the monthly alimatravir approach. These updates on enrollment and baseline characteristics will sit alongside the broader set of oral HIV data on daily, weekly and monthly regimens, underscoring the company’s continued focus on expanding oral treatment and prevention options for adults living with, or at risk of, HIV‑1.
Key Takeaways
- 01Merck is progressing a diversified oral HIV strategy that spans daily treatment, weekly regimens and monthly prevention in late‑stage trials.
- 02The FDA’s acceptance of two supplemental IDVYNSO applications, with a shared April 22, 2027 action date, positions the regimen for potential label expansion in both naïve and suppressed adults.
- 03Completion of adult enrollment in two Phase 3 alimatravir PrEP studies signals momentum in once‑monthly oral prevention, complementing progress in once‑weekly treatment combinations such as ISL/LEN and ISL/ULO.
References
- https://finance.yahoo.com/healthcare/articles/merck-mrk-pushes-ahead-oral-150650616.html?.tsrc=rss
- https://www.stocktitan.net/news/MRK/merck-to-present-new-data-from-its-broad-oral-hiv-portfolio-and-d8x3g23gn5yg.html
- https://rallies.ai/news/merck-to-present-phase-3-data-on-once-weekly-hiv-treatment-at-hiv-glasgow-2026-7d3462f7c49387fe
- https://nl.investing.com/news/company-news/merck-presenteert-hivbehandelings-en-preventiedata-op-conferentie-glasgow-93CH-958561